Novo Nordisk A/S (NVO) Position Lifted by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.4% during the 4th quarter, HoldingsChannel reports. The fund owned 13,702 shares of the company’s stock after acquiring an additional 324 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Novo Nordisk A/S were worth $632,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Bruderman Asset Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $29,000. Karp Capital Management Corp bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $43,000. We Are One Seven LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $46,000. Highwater Wealth Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $49,000. Finally, Berman Capital Advisors LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $49,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

NVO has been the subject of several research analyst reports. JPMorgan Chase & Co. raised Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a report on Monday, November 19th. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, November 26th. UBS Group reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Monday, November 26th. Finally, HSBC reissued a “sell” rating on shares of Novo Nordisk A/S in a report on Monday, November 26th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $52.31.

NYSE:NVO opened at $50.89 on Friday. The company has a market cap of $124.35 billion, a PE ratio of 20.19, a P/E/G ratio of 2.33 and a beta of 0.59. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $51.64.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Friday, February 1st. The company reported $0.54 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.03). The company had revenue of $4.55 billion for the quarter, compared to the consensus estimate of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. On average, sell-side analysts predict that Novo Nordisk A/S will post 2.58 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Position Lifted by Edmond DE Rothschild Holding S.A.” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://transcriptdaily.com/2019/03/17/novo-nordisk-a-s-nvo-position-lifted-by-edmond-de-rothschild-holding-s-a.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: Bull Market

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.